PremiumThe FlyBioAtla announces poster presentations at 2025 AACR meeting BioAtla price target lowered to $1 from $5 at Citizens JMP BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook PremiumThe FlyBioAtla reports Q4 Net loss ($14.9M) vs ($26.9M) last year BCAB Earnings Report this Week: Is It a Buy, Ahead of Earnings? BioAtla Awards Executive Bonuses and Stock Units PremiumMarket NewsMichael Burry Boosts His Bet on Chinese Stocks in Q3 BioAtla downgraded to Neutral from Buy at H.C. Wainwright BioAtla Reports Q3 2024 Financial Results and Clinical Advances